Talking With Educators

If your child has PI, it's important that other adults he or she comes in contact with—teachers, school nurses, and administrators—understand the condition and its treatment.

Share These Important Points to Help Educators Understand

  • Explain that PI stands for "primary immmunodeficiency disease," a genetic condition that makes your child susceptible to illness and infections.
  • Reassure your child's educators that your child poses no risk to other children. PI is not contagious and cannot be spread to other children or adults.
  • Let educators know that your child can participate in classroom and playground activities.
  • Describe how common germs can be especially harmful—even life-threatening—to your child's health.
  • Request a 504 plan, a plan that you and the school develop to ensure your child receives accommodations that will ensure academic success and access to the learning environment.

Ask Educators to Help Minimize Your Child's Exposure to Germs

  • Ask educators to encourage children to stay home from school when they are sick.
  • Request that if classmates do come to school sick that they be sent to the nurse's office or separated as much as possible from your child.
  • Appeal to the educator to reinforce good hygiene and encourage children to wash their hands after sneezing, blowing their noses, or using the restroom.

Alert Educators to Recognize Potential Problems

  • Ask educators to contact you if your child appears overly tired, feverish, chilled, or exhibits symptoms including cough, congestion, runny nose, earache, difficulty breathing or headache.
  • Communicate that your child's treatment experience may result in side effects, such as fatigue, headache, or swelling at infusion site.

Talking With Family & Friends

It's important for the entire family—especially siblings—to know about PI. They need to understand that your child can live a normal life with proper treatment.

With siblings, make them aware that having PI makes their brother or sister more susceptible to getting sick. If they have friends with colds or the flu, make it a point not to bring them home.

Tell your child's friends and their parents that PI is not contagious and cannot be spread to other children or adults. Let them know that having PI does not necessarily limit a child's activities.

Important Safety Information
Expand

Important Safety Information

WARNING: Thrombosis (blood clotting) can occur with immune globulin products, including Hizentra. Risk factors can include: advanced age, prolonged immobilization, a history of blood clotting or hyperviscosity (blood thickness), use of estrogens, installed vascular catheters, and cardiovascular risk factors.

If you are at high risk of thrombosis, your doctor will prescribe Hizentra at the minimum dose and infusion rate practicable and will monitor you for signs of thrombosis and hyperviscosity. Always drink sufficient fluids before administration.

Immune Globulin Subcutaneous (Human), Hizentra®, treats various forms of primary immunodeficiency (PI) in patients age 2 and over.

Tell your doctor if you have had a serious reaction to other immune globulin medicines or have been told you also have a deficiency of the immunoglobulin called IgA, as you might not be able to take Hizentra. You should not take Hizentra if you know you have hyperprolinemia (too much proline in your blood).

Infuse Hizentra under your skin only; do not inject into a blood vessel.

Allergic reactions can occur with Hizentra. If your doctor suspects you are having a bad allergic reaction or are going into shock, treatment will be discontinued. Immediately tell your doctor or go to the emergency room if you have signs of such a reaction, including hives, trouble breathing, wheezing, dizziness, or fainting.

Tell your doctor about any side effects that concern you. Immediately report symptoms that could indicate a blood clot, including pain and/or swelling of an arm or leg, with warmth over affected area; discoloration in arm or leg; unexplained shortness of breath; chest pain or discomfort that worsens with deep breathing; unexplained rapid pulse; and numbness or weakness on one side of the body. Your doctor will also monitor symptoms that could indicate hemolysis (destruction of red blood cells), and other potentially serious reactions that have been seen with Ig treatment, including aseptic meningitis syndrome (brain swelling); kidney problems; and transfusion-related acute lung injury.

The most common drug-related adverse reactions in the clinical trial for Hizentra were swelling, pain, redness, heat or itching at the site of injection; headache; back pain; diarrhea; tiredness; cough; rash; itching; nausea and vomiting.

Hizentra is made from components of human blood. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Before being treated with Hizentra, inform your doctor if you are pregnant, nursing or plan to become pregnant. Vaccines (such as measles, mumps and rubella) might not work well if you are using Hizentra. Before receiving any vaccine, tell the healthcare professional you are being treated with Hizentra.

Please see full prescribing information for Hizentra, including boxed warning and the patient product information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Collapse
Patient/Caregiver PI Learning Center Talking With Educators, Family, and Friends
CSL Behring
Hizentra is manufactured by CSL Behring AG and distributed by CSL Behring LLC.
Hizentra® is a registered trademark of CSL Behring AG.
© 2018 CSL Behring LLC. The product information presented on this site is intended for US residents only. HIZ/09-12-0016k(1) 9/2015